These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24920777)

  • 1. Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.
    Ross JE; Mendes RE; Jones RN
    J Clin Microbiol; 2014 Sep; 52(9):3399-401. PubMed ID: 24920777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.
    Farrell DJ; Mendes RE; Rhomberg PR; Jones RN
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5547-51. PubMed ID: 25022579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.
    Arhin FF; Tomfohrde K; Draghi DC; Aranza M; Parr TR; Sahm DF; Moeck G
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):92-5. PubMed ID: 18614315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.
    LaPlante KL; Mermel LA
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3166-9. PubMed ID: 19451302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin.
    Saravolatz LD; Pawlak J
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):159-161. PubMed ID: 30366652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of Disk Diffusion and MIC Quality Control Ranges for Nafithromycin (WCK 4873), a New Lactone-Ketolide.
    Hackel MA; Karlowsky JA; Dressel D; Sahm DF
    J Clin Microbiol; 2017 Oct; 55(10):3021-3027. PubMed ID: 28747372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3999-4004. PubMed ID: 22508304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin.
    Mendes RE; Farrell DJ; Flamm RK; Sader HS; Jones RN
    J Clin Microbiol; 2015 Aug; 53(8):2727-30. PubMed ID: 26019194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2015 Jan; 59(1):702-6. PubMed ID: 25348529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIC quality control guidelines for doxycycline when testing gram-positive control strains by the reference methods.
    Ross JE; Jones RN;
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):295-7. PubMed ID: 15582304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
    Ross JE; Scangarella-Oman NE; Miller LA; Sader HS; Jones RN
    J Clin Microbiol; 2011 Nov; 49(11):3928-30. PubMed ID: 21918031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility testing quality control studies with fosfomycin tromethamine.
    Fuchs PC; Barry AL; Brown SD
    Eur J Clin Microbiol Infect Dis; 1997 Jul; 16(7):538-40. PubMed ID: 9272392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
    Biedenbach DJ; Jones RN;
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):225-8. PubMed ID: 11777665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines.
    Sweeney D; Shinabarger DL; Smart JI; Bruss J; Pillar CM
    Diagn Microbiol Infect Dis; 2017 Sep; 89(1):83-85. PubMed ID: 28669676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.